Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-06-21
2005-06-21
Canella, Karen A. (Department: 1642)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S023000, C514S054000, C514S062000, C424S178100
Reexamination Certificate
active
06908903
ABSTRACT:
Cluster clearing agents (CCAs) and the use thereof are discussed. CCAs are composed of a hepatic clearance directing moiety which directs the biodistribution of a CCA-containing construct to hepatic clearance; and a binding moiety which mediates binding of the CCA to a compound for which rapid hepatic clearance is desired.
REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 4358439 (1982-11-01), Sieber et al.
patent: 4410688 (1983-10-01), Denkewalter et al.
patent: 4507466 (1985-03-01), Tomalia et al.
patent: 4678667 (1987-07-01), Meares et al.
patent: 4732863 (1988-03-01), Tomasi et al.
patent: 4863713 (1989-09-01), Goodwin et al.
patent: 4902502 (1990-02-01), Nitecki et al.
patent: 4904481 (1990-02-01), Fathman et al.
patent: 4923985 (1990-05-01), Gansow et al.
patent: 5089261 (1992-02-01), Nitecki et al.
patent: 5141966 (1992-08-01), Porath
patent: 5183660 (1993-02-01), Ikeda et al.
patent: 5215927 (1993-06-01), Berenson et al.
patent: 5256395 (1993-10-01), Barbet et al.
patent: 5281698 (1994-01-01), Nitecki
patent: 5342940 (1994-08-01), Ono et al.
patent: 031 303 (1981-07-01), None
patent: 251 494 (1988-01-01), None
patent: 451 824 (1991-10-01), None
patent: 496 074 (1992-07-01), None
patent: 519 554 (1992-12-01), None
patent: PCT/GB89/00427 (1989-04-01), None
patent: WO 88/08422 (1988-11-01), None
patent: WO 89/10140 (1989-11-01), None
patent: WO 90/12050 (1990-10-01), None
patent: WO 92/12730 (1992-08-01), None
patent: WO 95/14493 (1993-06-01), None
patent: WO 93/15210 (1993-08-01), None
patent: WO 93/25240 (1993-12-01), None
patent: WO 94/04702 (1994-03-01), None
patent: WO 94/11398 (1994-05-01), None
patent: WO 94/17829 (1994-08-01), None
patent: WO 95/15978 (1995-03-01), None
patent: WO 95/15770 (1995-06-01), None
patent: WO 95/15979 (1995-06-01), None
Abuchowski et al., “Alteration of Immunological Properties of Bovine Serum Albumin by Covalent Attachment of Polyethylene Glycol,”J. of Biological Chem.252(11):3578-3581, 1997.
Abuchowski et al., “Cancer Therapy with Chemically Modified Enzymes. I. Antitumor Properties of Polyethylene Glycol-Asparaginase Conjugates,”Can. Biochem. Biophys.7:175-186, 1984.
Axworthy et al., “Antibody Pretargeting For Radioimmunotherapy: A Three-Step Approach In Tumored Nude Mice,”The Journal of Nuclear Medicine; Proceedings of the 39thAnnual Meeting33: p. 880, Abstract No. 234, 1992.
Basch et al., inJournal of Immunological Methods56:269-280, 1983.
Beauchamp et al., “A New Procedure for the Synthesis of Polyethylene Glycol-Protein Adducts; Effects on Function, Receptor Recognition, and Clearance of Superoxide Dismutase, Lactoferrin, and α2-Macroglobulin,”Analytical Biochem131:25-33, 1983.
Biessen et al., “Synthesis of Cluster Galatosides with High Affinity for the Hepatic Asialoglycoprotein Receptor,”J. Med. Chem.38:1538-1546, 1995.
Bodenmuller et al., inEmbo. J.5(8):1825-9, 1986.
Boehringer Mannheimn Catalog—1991, pp. 49 and 59.
Chaudhari et al., “Coupling of Amino Acids and Amino Sugars with Cyanuric Chloride (2,4,6-Trichloro-s-triazine)1,”Canadian Journal of Chemistry50(13):1987-1990, 1972.
Chen et al., “Properties of Two Urate Oxidases Modified by the Covalent Attachment of Poly (ethylene Glycol),”Biochemica et Biophysica Acta660:293-298, 1981.
Davis et al., “Alteration of the circulating life and antigenic properties of bovine adenosine deaminase in mice by attchment of polyethylene glycol,”Clin. Exp. Immunol.46:649-652, 1981.
Findeis, “Stepwise synthesis of a GalNAc-containing cluster glycoside ligand of the asialoglycoprotein receptor,”Int. J. Peptide Protein Res.43:477-485, 1994.
Galli et al., “A Radiopharmaceutical for the Study of the Liver:99mTc-DTPA-Asialo-Orosomucoid,”The Journal of Nuclear Medicine and Allied Sciences,pp. 110-116, Apr.-Jun. 1988.
Goodwin and Hnatowich, Letter to the Editor/Reply, inJ. Nucl. Med.32(4):750-751, 1991.
Goodwin et al., “New Methods for Localizing Infection: A Role for Avidin-Biotin?,”The Journal of Nuclear Medicine33(10):1816-1818, 1992.
Goodwin et al., “Pharmacokinetics of Biotin-Chelate Conjugates for Pretargeted Avidin-Biotin Immunoscintigraphy,”J. Nucl. Med.,p. 880, Abstract No. 232, 1992.
Goodwin et al., “Pretargeted Immunoscintigraphy: Effect of Hapten Valency on Murine Tumor Uptake,”The Journal of Nuclear Medicine33(11): 2006-2103, 1992.
Green, “The Use of [14C] Biotin for Kinetic Studies and for Assay,”Biochem. J.89:585, 1963.
Haensler et al., “Synthesis and Characterization of a Trigalactosylated Bisacridine Compound to Target DNA to Hepatocytes,”Bioconjugate Chem.4:85-93, 1993.
Hnatowich et al., “Investigations of Avidin and Biotin for Imaging Applications,” 28(8): 1294-1302, 1987.
Hubbard et al., “Suppression of the Anti-DNP IgE Response with Tolerogenic Conjugates of DNP with Polyvinyl Alcohol,”J. of Immunology126(2), 1981.
Jansen et al., “Hepatic Endocytosis of Various Types of Mannose-terminated Albumins,”The Journal of Biological Chemistry266(5): 3343-3348, 1991.
Kalofonos et al., “Imaging of Tumor in Patients with Indium-111-Labeled Biotin and Streptavidin-Conjugated Antibodies: Preliminary Communication,”J. Nucl. Med.31(11):1791-1796, 1990.
Koch and Macke, “99mTc Labeled Biotin Conjugate in a Tumor ‘Pretargeting’ Approach with Monoclonal Antibodies,”Angew. Chem. Intl. Ed. Engl.31(11):1507-1509, 1992.
Krantz et al., “Attachment of Thioglycosides to Proteins: Enhancement of Liver Membrane Binding,”Biochemistry15(18):3963-3968, 1976.
Krull et al., “Solid-phase derivatization reactions for biomedical liquid chromatography,”J. Chromatography B: Biomedical Applications659:19-50, 1994.
Lee et al., “2-Imino-2methoxyethyl 1-Thioglycosides: New Reagents for Attaching Sugars to Proteins,”Biochemistry15(18):3956-3962, 1976.
Lee et al., “Abrogation of the Antibenzylpenciloyl (BPO) IgE Response with BPO-Polyvinyl Alcohol Conjugates,”Int. Archs Allergy appl. Immun.63:1-13, 1980.
Lee et al., “New Synthetic Cluster Ligands for Galactose/N-Acetylgalactosamine-Specific Lectin of Mammalian Liver,”Biochemistry23:4255-4261, 1984.
Lee et al., “Preparation of Cluster Glycosides of N-Acetylgalactosamine That Have Subnanomolar Binding Constants Towards the Mammalian Hepatic Gal/GalNAc-specific Receptor,”Glycoconjugate J.4:317-328, 1987.
Lee et al., “Suppresion of Reaginic Antibodies with Modified Allergens,”Int. Arch Allergy appl. Immun.63:1-13, 1980.
Leonard et al., “Synthesis of monomethoxypolyoxyethylene-Bound haemoglobins,”Tetrahedron40(9):1581-1584, 1984.
Ling et al., “A General Study of the Binding and Separation in Partition Affinity Ligand Assay. Immunoassay of β2-Microglobulin,”J. Immunological Methods59:327-337, 1983.
Makhlouf et al., “Antisera Specificities to β-D-Galactopyranside Cluster Ligands,”Carbohydrate Research132:93-103, 1984.
Mattes, J., “Biodistribution of Antibodies After Intraperitoneal or Intravenous Injection and Effect of Caqrbohydrate Modifications,” 79(4):855-863, 1987.
Mauk et al., “Targeting of lipid vesicles: Specificity of carbohydrate receptor analogues for leukocytes in mice,”Proc. Natl. Acad. Sci. USA77:4430-4434, 1980.
Mauk et al., “Vesicle Targeting: Timed Release and Specificity for Leukocytes in Mice by Subcutaneous Injection,”Science207(18), 1980.
Mckee et al., “Preparation of Asialoorosomucoid-Polysine Conjugates,”Bioconjugate Chem.5:306-311, 1994.
Merwin et al., “Targeted Delivery of DNA Using YEE(GaINAcAH)x, a Synthetic Glycopeptide Ligand for the Asialoglycoprotein Receptor,”Bioconjugate Chem.5:612-620, 1994.
Morell et al., “The Role of Sialic Acid in Determining the Survival of Glycoproteins in the Circulation,”Journ
Axworthy Donald B.
Theodore Louis J.
Aletheon Pharmaceuticals, Inc.
Canella Karen A.
Seed Intellectual Property Law Group PLLC
LandOfFree
Cluster clearing agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cluster clearing agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cluster clearing agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3502127